ARTICLE | Clinical News
ASP2408: Phase I started
February 7, 2011 8:00 AM UTC
The companies' Perseid Therapeutics LLC JV began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate single ascending-doses of IV ASP2408 in 65 healthy volunteers. The ...